Fisher Asset Management LLC Boosts Holdings in GSK plc (NYSE:GSK)

Fisher Asset Management LLC increased its position in GSK plc (NYSE:GSK - Free Report) by 10.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 15,065,558 shares of the pharmaceutical company's stock after acquiring an additional 1,465,165 shares during the quarter. Fisher Asset Management LLC owned about 0.73% of GSK worth $558,330,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in shares of GSK by 2,816.7% during the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company's stock worth $26,000 after purchasing an additional 676 shares in the last quarter. Larson Financial Group LLC boosted its position in GSK by 271.8% during the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company's stock valued at $32,000 after buying an additional 647 shares during the period. BKM Wealth Management LLC bought a new stake in GSK in the 4th quarter worth $32,000. Jones Financial Companies Lllp increased its position in shares of GSK by 62.2% in the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company's stock valued at $48,000 after acquiring an additional 509 shares during the period. Finally, Princeton Global Asset Management LLC boosted its holdings in shares of GSK by 54.3% during the fourth quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company's stock worth $56,000 after purchasing an additional 533 shares during the period. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

GSK stock traded up $0.16 during trading on Friday, reaching $43.51. The company's stock had a trading volume of 4,048,065 shares, compared to its average volume of 3,508,426. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. GSK plc has a 1 year low of $33.33 and a 1 year high of $43.84. The company's fifty day moving average is $41.85 and its 200-day moving average is $39.09. The company has a market capitalization of $90.17 billion, a P/E ratio of 15.76, a price-to-earnings-growth ratio of 1.50 and a beta of 0.65.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts' consensus estimates of $0.76 by ($0.04). GSK had a net margin of 14.62% and a return on equity of 52.42%. The firm had revenue of $10 billion for the quarter, compared to analysts' expectations of $9.79 billion. On average, research analysts expect that GSK plc will post 4.03 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be paid a $0.3762 dividend. The ex-dividend date is Thursday, May 16th. This represents a $1.50 annualized dividend and a dividend yield of 3.46%. This is an increase from GSK's previous quarterly dividend of $0.36. GSK's dividend payout ratio is currently 57.61%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Guggenheim upgraded GSK from a "neutral" rating to a "buy" rating in a report on Monday, March 4th. Citigroup upgraded shares of GSK from a "neutral" rating to a "buy" rating in a report on Tuesday, February 13th. Finally, Morgan Stanley began coverage on shares of GSK in a report on Tuesday, January 23rd. They set an "equal weight" rating for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, GSK has an average rating of "Moderate Buy".

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.